This text is a result of machine translation.
Shuidi company has established a new pharmaceutical innovation division to further develop the pharmaceutical direction
F-star to be acquired by China biopharmaceutical with USD 161million
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
East China medicine "liraglutide" goes to sea
Nearly half of the equity of two subsidiaries of Tongrentang was transferred to Tongrentang medical care
Baiyunshan: suspension of the spin off of Guangzhou Pharmaceutical for overseas listing
Germany Merck "cetuximab" new indications for head and neck squamous cell carcinoma approved in China
Biotech Firm ImmuneOnco Submitted Listing Application on the Main Board of HKEX
ImmuneOnco, focusing on developing new-generation tumor immunotherapeutic, will further accelerate the development of other promising drug candidates targeting checkpoints of innate and adaptive immunity.
Updated 31 mins ago
Yanye new crown drug 3CL protein inhibitor has been suspended approval
Yi Ming ang Ke delivers a statement to the main board of the Hong Kong stock exchange to develop a new generation of tumor immunotherapy
Fosun pharma and Amgen have reached cooperation to accelerate the commercialization of two innovative drugs in China
BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious
BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.
Jun 24, 2022 12:13 PM
And platinum medicine b7h4x4-1bb bispecific antibody were approved by FDA for new drug research
Fosun pharma and Amgen have reached cooperation to accelerate the commercialization of two innovative drugs in China
It is expected to achieve functional cure of chronic hepatitis B! GSK antisense therapy phase IIB positive clinical results
Aibo biology: cooperate with Jiahe biology to jointly develop tumor mRNA drugs